Kenya’s HIV prevention strategy has entered a new phase with the arrival of 21,000 starter doses of Lenacapavir, a long-acting injectable pre-exposure prophylaxis (PrEP). Confirmed on February 17, 2026, through collaboration between the Ministry of Health and the Global Fund, the rollout makes Kenya the first East African country to operationalise this advanced prevention option. The shift moves away from daily oral PrEP toward a sustained-release model that could significantly reduce new infections among high-risk but HIV-negative populations. 

Lenacapavir works by inhibiting the HIV-1 capsid protein, disrupting multiple stages of viral replication. Administered as a subcutaneous injection every six months, it maintains protective drug levels without the daily adherence burden associated with oral PrEP—one of the main barriers to prevention success. However, it is strictly for HIV-negative individuals at substantial risk and is neither a treatment nor a vaccine. Routine HIV testing before each injection remains essential to prevent drug resistance. 

The rollout will follow a phased model beginning in March 2026, targeting 15 high-burden counties identified through epidemiological surveillance. This approach allows authorities to assess real-world effectiveness, pharmacovigilance, and service delivery logistics before national scale-up. 

Long-acting injectable PrEP offers operational advantages: reduced adherence challenges, greater discretion that may lower stigma, and improved continuity of protection for mobile or underserved populations. It complements Kenya’s broader combination prevention framework, which includes barrier methods, testing services, and sexual health education. 

Safety monitoring will be central, with healthcare providers tracking injection-site reactions and adverse events as real-world data emerge. The introduction also reflects advances in sustained-release drug delivery, ensuring stable protective concentrations over extended periods. 

Priority groups include youth, sex workers, serodiscordant couples, and other high-transmission networks.  

Kenya’s early adoption may generate insights for regional health systems considering similar strategies. Ultimately, success will be measured by lower infection rates, improved prevention coverage, and stronger engagement in HIV prevention services.